for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Reata Pharmaceuticals Inc

RETA.OQ

Latest Trade

94.39USD

Change

2.57(+2.80%)

Volume

333,514

Today's Range

91.60

 - 

95.30

52 Week Range

47.50

 - 

104.34

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
91.82
Open
92.06
Volume
333,514
3M AVG Volume
4.89
Today's High
95.30
Today's Low
91.60
52 Week High
104.34
52 Week Low
47.50
Shares Out (MIL)
30.11
Market Cap (MIL)
2,841.74
Forward P/E
-20.41
Dividend (Yield %)
--

Latest Developments

More

Reata Pharmaceuticals Inc. Q2 Loss Per Share $1.14

Reata Pharmaceuticals Reports Q1 Results

Reata Pharmaceuticals Q4 Loss Per Share $0.86

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Reata Pharmaceuticals Inc

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.

Industry

Biotechnology & Drugs

Contact Info

2801 Gateway Dr Ste 150

+1.972.8652206

https://reatapharma.com/

Executive Leadership

J. Warren Huff

Chairman of the Board, President, Chief Executive Officer

Manmeet S. Soni

Chief Financial Officer, Executive Vice President

Dawn C. Bir

Executive Vice President, Chief Commercial Officer

Colin John Meyer

Chief Medical Officer and Executive Vice President, Product Development

Jason Douglas Wilson

Executive Vice President - Operations

Key Stats

1.14 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.0K
EPS (USD)

2016

-0.310

2017

-1.990

2018

-2.910

2019(E)

-4.626
Price To Earnings (TTM)
--
Price To Sales (TTM)
97.22
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-68.20
Return on Equity (TTM)
-50.48

Latest News

BRIEF-Reata Pharmaceuticals Posts Q1 Earnings Per Share $0.16

* REATA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS

BRIEF-Reata Pharmaceuticals Announces New Preclinical Data Of Omaveloxolone

* REATA ANNOUNCES NEW PRECLINICAL DATA DEMONSTRATING THE POTENTIAL OF OMAVELOXOLONE IN THE TREATMENT OF FRIEDREICH’S ATAXIA AND OTHER SEVERE NEUROLOGICAL DISEASES Source text for Eikon: Further company coverage:

BRIEF-Reata Provides Update On Phase 2 Portion Of Cardinal Study Of Bardoxolone Methyl In Patients With Alport Syndrome

* REATA PROVIDES UPDATE ON THE PHASE 2 PORTION OF THE CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME

BRIEF-Reata Announces That Kyowa Hakko Kirin Received Sakigake Priority Review Designation For Bardoxolone Methyl In Japan

* REATA ANNOUNCES THAT KYOWA HAKKO KIRIN RECEIVED SAKIGAKE PRIORITY REVIEW DESIGNATION FOR BARDOXOLONE METHYL IN JAPAN Source text for Eikon: Further company coverage:

BRIEF-Reata Announces Positive Top-Line Data For Treatment Of PH-ILD With Bardoxolone Methyl From Phase 2 Lariat Trial

* REATA ANNOUNCES POSITIVE TOP-LINE DATA FOR TREATMENT OF PH-ILD WITH BARDOXOLONE METHYL FROM THE PHASE 2 LARIAT TRIAL

BRIEF-Reata Pharmaceuticals Inc. Announces Q4 Loss Per Share $0.64

* REATA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS

BRIEF-Reata Announces Top-Line Data From Study Of Patients With Mitochondrial Myopathies

* REATA ANNOUNCES TOP-LINE DATA FROM THE DOSE-ESCALATION COHORTS OF THE PHASE 2 MOTOR STUDY OF OMAVELOXOLONE IN PATIENTS WITH MITOCHONDRIAL MYOPATHIES Source text for Eikon: Further company coverage:

BRIEF-Reata Provides Program Update On Phase 2 Rare Renal Clinical Trials

* REATA PROVIDES PROGRAM UPDATE ON PHASE 2 RARE RENAL CLINICAL TRIALS

BRIEF-Reata Announces Improvements In Kidney Function With Bardoxolone Methyl Maintained For Two Years In Pah Patients From Lariat Trial

* REATA ANNOUNCES IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE METHYL MAINTAINED FOR TWO YEARS IN PAH PATIENTS FROM LARIAT TRIAL Source text for Eikon: Further company coverage:

BRIEF-Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko

* REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK)

BRIEF-Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock

* Files for offering of up to $50.0 million of shares of Class A common stock - SEC filing Source text : (http://bit.ly/2AG2XNP) Further company coverage:

BRIEF-Reata Pharmaceuticals Q3 loss per share $0.50

* Reata Pharmaceuticals Inc announces third quarter 2017 financial and operating results

BRIEF-Reata Pharmaceuticals enters first amendment to loan and security agreement​

* Reata Pharmaceuticals says on November 3, co entered into a first amendment to loan and security agreement - SEC filing

BRIEF-Reata provides update on Bardoxolone Methyl from American Society of Nephrology Kidney Week Meeting

* Reata provides update on bardoxolone methyl from the american society of nephrology kidney week meeting

BRIEF-Reata Pharmaceuticals says top-line data to be available in 2019 for omaveloxolone​

* Reata Pharmaceuticals Inc - announces first patient enrolled in Part 2 of Moxie study of omaveloxolone for treatment of Friedreich's Ataxia

BRIEF-Reata Pharma receives orphan drug designation for Omaveloxolone

* Reata Pharmaceuticals Inc receives orphan drug designation for Omaveloxolone for the treatment of malignant melanoma

BRIEF-Reata Pharmaceuticals Q2 loss per share $0.52

* Reata pharmaceuticals Inc announces second quarter 2017 financial and operating results

BRIEF-Reata announces first patient enrolled in Phase 3 Cardinal trial of Bardoxolone Methyl in the treatment of chronic kidney disease due to Alport Syndrome

* Reata announces first patient enrolled in phase 3 cardinal trial of Bardoxolone Methyl in the treatment of chronic kidney disease due to Alport Syndrome Source text for Eikon: Further company coverage:

BRIEF-William Rose reports 15.4 percent stake in Reata Pharmaceuticals Inc as on Aug 1

* William Rose reports 15.4 percent stake in Reata Pharmaceuticals Inc as on Aug 1 - SEC filing

BRIEF-Reata Pharmaceuticals announces pricing of Class A common stock public offering

* Reata Pharmaceuticals, Inc. announces pricing of Class A common stock public offering

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up